| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2018 | Adiposity, inflammation, and breast cancer pathogenesis in Asian Women | Iyengar N.M.; I-CHUN CHEN ; Zhou X.K.; Giri D.D.; Falcone D.J.; Winston L.A.; Wang H.; Williams S.; YEN-SHEN LU ; Hsueh T.-H.; ANN-LII CHENG ; Hudis C.A.; CHING-HUNG LIN ; Dannenberg A.J. | Cancer Prevention Research | 31 | 29 | |
| 2019 | Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer | Andr? F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo H.S; Iwata H; Conte P; Mayer I.A; Kaufman B; Yamashita T; YEN-SHEN LU ; Inoue K; Takahashi M; P?pai Z; Longin A.-S; Mills D; Wilke C; Hirawat S; Juric D. | New England Journal of Medicine | 1167 | 1083 | |
| 2021 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2�Vnegative advanced breast cancer: final overall survival results from SOLAR-1 | Andr? F.; Ciruelos E.M.; Juric D.; Loibl S.; Campone M.; Mayer I.A.; Rubovszky G.; Yamashita T.; Kaufman B.; YEN-SHEN LU ; Inoue K.; P?pai Z.; Takahashi M.; Ghaznawi F.; Mills D.; Kaper M.; Miller M.; Conte P.F.; Iwata H.; Rugo H.S. | Annals of Oncology | 181 | 158 | |
| 2021 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens | Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU ; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. | Breast Cancer Research and Treatment | 4 | 4 | |
| 2004 | Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI | YEUN-CHUNG CHANG ; CHIUN-SHENG HUANG ; Liu Y.-J.; Chen J.-H.; YEN-SHEN LU ; WEN-YIH TSENG | Physics in Medicine and Biology | 70 | 62 | |
| 2021 | Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients | I-CHUN CHEN ; Hu, Fu-Chang; CHING-HUNG LIN ; Huang, Shu-Min; DWANG-YING CHANG ; ANN-LII CHENG ; YEN-SHEN LU | Breast (Edinburgh, Scotland) | 1 | 1 | |
| 2011 | The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer | Wang J.; TIFFANY TING-FANG SHIH ; RUOH-FANG YEN ; YEN-SHEN LU ; Chen C.-Y.; TSUI-LIEN MAO ; CHING-HUNG LIN ; WEN-HUNG KUO ; Tsai Y.-S.; KING-JEN CHANG ; KUO-LIONG CHIEN | Academic Radiology | 10 | 7 | |
| 2018 | Association of pregnancy and mortality in women diagnosed with breast cancer: A Nationwide Population Based Study in Taiwan | Chuang S.-C.; CHING-HUNG LIN ; YEN-SHEN LU ; Hsiung C.A. | International Journal of Cancer | 7 | 8 | |
| 2015 | Associations between medical conditions and breast cancer risk in asians: A nationwide population-based study in Taiwan | Chuang S.-C.; Wu G.-J.; YEN-SHEN LU ; CHING-HUNG LIN ; Hsiung C.A. | PLoS ONE | 26 | 26 | |
| 2020 | Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models (Scientific Reports, (2019), 9, 1, (10898), 10.1038/s41598-019-45319-4) | Kuo, C.-T.; Chen, C.-L.; Li, C.-C.; Huang, G.-S.; Ma, W.-Y.; Hsu, W.-F.; CHING-HUNG LIN ; YEN-SHEN LU ; ANDREW WO | Scientific Reports | 0 | 0 | |
| 2011 | Axillary vs sentinel lymph node dissectionfor invasive breast cancer [2] | I-CHUN CHEN ; CHING-HUNG LIN ; YEN-SHEN LU | JAMA - Journal of the American Medical Association | 9 | 4 | |
| 2002 | Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells | Chuang S.-E.; Yeh P.-Y.; YEN-SHEN LU ; Lai G.-M.; Liao C.-M.; Gao M.; ANN-LII CHENG | Biochemical Pharmacology | 154 | 136 | |
| 2013 | Benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patients | Dewi S; Larsen S; Srimuninnimit V; YEN-SHEN LU ; Manuaba T; Lindk?r-Jensen S. | Open Breast Cancer Journal | 7 | 0 | |
| 2016 | Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis | I-CHUN CHEN ; CHING-HUNG LIN ; I-SHIOW JAN ; ANN-LII CHENG ; YEN-SHEN LU | Journal of the Formosan Medical Association | 15 | 11 | |
| 2015 | Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy | YEN-SHEN LU ; WEI-WU CHEN ; CHING-HUNG LIN ; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; BANG-BIN CHEN ; Chao T.-C.; Huang S.-M.; CHIUN-SHENG HUANG ; TIFFANY TING-FANG SHIH ; ANN-LII CHENG ; Taiwan Breast Cancer Consortium | Clinical Cancer Research | 61 | 53 | |
| 2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
| 2020 | A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women | Lien, Guang-Wen; WU-SHIUN HSIEH ; WEN-HUNG KUO ; CHING-HUA KUO ; Huang, Ching-Chun; YUE-LIANG GUO; DWANG-YING CHANG ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; ANN-LII CHENG ; CHING-HUNG LIN ; PAU-CHUNG CHEN | Environment International | 36 | 29 | |
| 2011 | Cisplatin as an active treatment in zoledronate-refractory hypercalcemia | PO-HAN LIN ; Chiu C.-F.; YEN-SHEN LU | Annals of Oncology | 1 | 1 | |
| 2022 | Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices | WEI-LI MA ; Chang, Dwan-Ying; CHING-HUNG LIN ; KAO-LANG LIU ; PO-CHIN LIANG ; HUANG-CHUN LIEN ; Hu, Chan-Chuan; Huang, Ling-Yun; Yeh, Yi-Chun; YEN-SHEN LU | The oncologist | 0 | 0 | |
| 2016 | Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer | I-CHUN CHEN ; Chang Y.-C.; YEN-SHEN LU ; KUEI-PIN CHUNG ; CHIUN-SHENG HUANG ; TZU-PIN LU ; WEN-HUNG KUO ; Wang M.-Y.; KUAN-TING KUO ; Wu P.-F.; Hsueh T.-H.; Shen C.-Y.; CHING-HUNG LIN ; ANN-LII CHENG | Scientific Reports | 15 | 15 | |
